This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings as well as sales in the second quarter. It raises earnings expectations for 2018 but slightly lowers the sales range.
Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.
Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.
Merck's Keytruda Improves Survival in Head/Neck Cancer Study
by Zacks Equity Research
Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Is a Beat in Store for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.
Healthcare ETFs to Buy on Solid Q2 Earnings Expectations
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.
AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Roche's Flu Drug Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.
Pacira Focused on Exparel Development Amid Competition
by Zacks Equity Research
Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
by Zacks Equity Research
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Is a Surprise in the Cards for Novartis in Q2 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity
by Zacks Equity Research
Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.
Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
by Zacks Equity Research
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
Moving Average Crossover Alert: Amgen (AMGN)
by Zacks Equity Research
Amgen Inc. (AMGN) is looking like an interesting pick from a technical perspective
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.